Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view
Expert Opin Biol Ther
.
2020 Jun;20(6):539-544.
doi: 10.1080/14712598.2020.1733965.
Epub 2020 Feb 25.
Authors
Alessia Cimadamore
1
,
Marina Scarpelli
1
,
Francesco Massari
2
,
Markus Eckstein
3
,
Thomas Gevaert
4
5
6
,
Liang Cheng
7
,
Antonio Lopez-Beltran
8
,
Rodolfo Montironi
1
Affiliations
1
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
2
Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
3
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Erlangen, Germany.
4
Department of Urology, UZ Leuven, Leuven, Belgium.
5
Organ Systems, KU Leuven, Leuven, Belgium.
6
Department of Pathology, AZ Klina, Brasschaat, Belgium.
7
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
8
Department of Pathology and Surgery, Cordoba University, Faculty of Medicine, Cordoba, Spain.
PMID:
32081061
DOI:
10.1080/14712598.2020.1733965
No abstract available
Keywords:
Bladder cancer; PD-L1; PD-L1 testing; immunohistochemistry; immunotherapy.
Publication types
Editorial
Comment
MeSH terms
Carcinoma, Transitional Cell*
Humans
Immunotherapy
Pathologists*